Comparison between the effects of adding Butorphanol and Nalbuphine as adjuvants in spinal anesthesia

A comparative evaluation of efficacy of intrathecal Butorphanol and Nalbuphine as an adjuvant to Bupivacaine 0.5% heavy for lower limb surgeries

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009952

Enrollment

Registered

2017-09-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients posted for lower limb surgeries

Interventions

Intervention1: Butorphanol: it is an opioid agonist-antagonist being used in this trial in dose of 25 mcg as an adjuvant in subarachnoid block. Total duration of therapy is 2 hours Control Interventio

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA Grade I AND II 2. With Informed Consent 3. elective lower limb surgery

Exclusion criteria

Exclusion criteria: 1. Patient refusal 2. Allergy to any anesthetic drug 3. Infection at the site of injection 4. Patient on anticoagulants or bleeding disorder 5. ASA III and IV 6. Patients on tranquilizers, hypnotics, sedatives, and other psychotropic drugs. 7. Duration of surgery > 2 hrs

Design outcomes

Primary

Measure	Time frame
Motor Bromage score of 4, Sensory loss of atleast upto T10Timepoint: 3 hours	—

Secondary

Measure	Time frame
VAS Score of more than 3Timepoint: 3 hours	—

Countries

India

Contacts

Public ContactNeeharika Arora

Shri Ram Murti Smarak Institute of Medical Sciences

mohit4605@gmail.com8586840508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026